Systemic immunotherapy

Phase 2Small molecule

TTianjin Medical University Second Hospital

Systemic immunotherapy is one of 43 small molecule programs targeting Bladder Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bladder CancerActive, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

378 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

57 2

Keytruda

Merck & Co.

Phase 3

31 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

61 4

Padcev

Pfizer

Phase 3

13 5

Trexall

Alnylam Pharmaceuticals

Phase 3

13 6

Gemzar

GGynecologic Oncology Group

Phase 3

24 7

Velban

Eli Lilly

Phase 3

8 8

Adriamycin

Pfizer

Phase 3

6 9

Javlor

Bristol-Myers Squibb

Phase 3

5 10

Iressa

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Bladder Cancer

NCT07475403

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07475403·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Systemic immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Systemic immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Systemic immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Second Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTianjin Medical University Second Hospital

Systemic immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News